The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Official Title: Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Study ID: NCT02197637
Brief Summary: The purpose of this study is to determine whether oral vinorelbine is effective in the treatment of children with progressive or recurrent unresectable low grade glioma.
Detailed Description: The aim of this study is to determine efficacy of oral vinorelbine in children with progressive or recurrent unresectable low grade glioma, in addition to safety, pharmacokinetic, pharmacogenetic, medical costs and quality of life.
Minimum Age: 6 Years
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
CHU d'Angers, Angers, , France
CHU de Bordeaux, Bordeaux, , France
CHU de Grenoble, Grenoble, , France
Centre Oscar Lambret, Lille, , France
CHU de Limoges, Limoges, , France
Centre Léon Bérard, Lyon, , France
Hôpital de la TIMONE, Marseille, , France
CHRU Arnaud de Villeneuve, Montpellier, , France
CHU de Nancy, Nancy, , France
Institut Curie, Paris, , France
CHU de Reims, Reims, , France
CHU de Rennes - Hôpital Sud, Rennes, , France
CHU de Rouen, Rouen, , France
Hôpital Hautepierre, Strasbourg, , France
Hôpital des Enfants, Toulouse, , France
Institut Gustave Roussy, Villejuif, , France
Name: Pierre LEBLOND, MD, PhD
Affiliation: Centre Oscar Lambret, Lille, France
Role: PRINCIPAL_INVESTIGATOR
Name: Nicolas ANDRE, MD, PhD
Affiliation: Hôpital La Timone, Marseille, France
Role: PRINCIPAL_INVESTIGATOR